Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19 MESHD

    Authors: Justin Jee; Aaron J Stonestrom; Sean Devlin; Teresa Nguyentran; Beatriz Wills; Varun Narendra; Michael B Foote; Melissa Lumish; Santosha Vardhana; Stephen Pastores; Neha Korde; Dhwani Patel; Steven Horwitz; Michael Scordo; Anthony Daniyan

    doi:10.1101/2020.08.11.20145458 Date: 2020-08-12 Source: medRxiv

    Background Corticosteroids, anti- CD20 HGNC agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer MESHD. How these agents impact patients with cancer MESHD who are infected with SARS-CoV-2 remains unclear. Methods We retrospectively investigated associations between SARS-CoV-2-associated respiratory failure MESHD or death MESHD with receipt of the aforementioned medications and with pre- COVID-19 MESHD neutropenia MESHD. The study included all cancer MESHD patients diagnosed with SARS-CoV-2 at Memorial Sloan Kettering Cancer Center until June 2, 2020 (N=820). We controlled for cancer MESHD-related characteristics known to predispose to worse COVID-19 MESHD. To address that more acutely ill patients receive therapeutic corticosteroids, we examined patient subsets based on different levels of respiratory support: <=2 L/min supplemental oxygen, >2L/min supplemental oxygen, and advanced respiratory support prior to death. Results Corticosteroid administration was associated with worse outcomes in the pre-2L supplemental oxygen cohort; no statistically significant difference was observed in the >2L/min supplemental oxygen and post-critical cohorts. Interleukin-6 HGNC ( IL-6 HGNC) and C-reactive protein HGNC ( CRP HGNC) levels were lower, and ferritin levels were higher, after corticosteroid administration. In patients with metastatic thoracic cancer MESHD, 9 of 25 (36%) and 10 of 31 (32%) had respiratory failure MESHD or death MESHD among those who did and did not receive immunotherapy, respectively. Seven of 23 (30%) and 52 of 187 (28%) patients with hematologic cancer MESHD had respiratory failure MESHD or death MESHD among those who did and did not receive anti- CD20 HGNC therapy, respectively. Chemotherapy itself was not associated with worse outcomes, but pre- COVID-19 MESHD neutropenia MESHD was associated with worse COVID-19 MESHD course. Relative prevalence of chemotherapy-associated neutropenia MESHD in previous studies may account for different conclusions regarding the risks of chemotherapy in patients with COVID-19 MESHD. In the absence of prospective studies and evidence-based guidelines, our data may aid providers looking to assess the risks and benefits of these agents in caring for cancer MESHD patients in the COVID-19 MESHD era.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.